Suboxone Titration Schedule
For opioid use disorder treatment, initiate Suboxone with 8 mg on Day 1, followed by 16 mg on Day 2, then continue with 16 mg daily as the target maintenance dose. This represents the standard FDA-approved induction protocol that has demonstrated superior efficacy compared to placebo in controlled trials 1.
Standard Induction Protocol (Opioid Use Disorder)
The FDA label provides clear guidance based on clinical trial data:
- Day 1: 8 mg buprenorphine (given as SUBUTEX initially to avoid precipitated withdrawal)
- Day 2: 16 mg buprenorphine (two 8 mg tablets)
- Day 3 onward: Switch to SUBOXONE (buprenorphine/naloxone combination) at 16 mg daily
Critical timing requirement: Patients must be in mild opioid withdrawal before the first dose to prevent precipitated withdrawal 2. This is non-negotiable due to buprenorphine's high affinity for the μ-opioid receptor.
Dose Range and Flexibility
While 16 mg daily is the standard target, clinical trials demonstrate effectiveness across a range:
- Effective dose range: 4-24 mg daily (tablet equivalent) 1
- Most common maintenance dose: 8-16 mg daily for patients previously using >120 mg morphine equivalent daily dose 3, 4
- Doses below 4 mg daily showed inferior outcomes in controlled trials 1
The medication should be held sublingually for 5-10 minutes until completely dissolved 1.
Alternative Dosing Schedules
Less-than-daily dosing is possible but requires dose adjustment: administer multiples of the daily dose to cover the increased interval between doses 5. For example, if dosing every other day, give double the daily dose.
Tapering Schedule (When Discontinuing)
If discontinuation is planned, gradual dose reduction is strongly preferred over rapid taper or abrupt cessation 5. However, evidence shows that:
- 7-day taper: 44% opioid-free at taper completion
- 28-day taper: 30% opioid-free at taper completion
Paradoxically, the shorter 7-day taper showed better immediate outcomes, though both groups had similar poor outcomes (12-18% opioid-free) at 3-month follow-up 6. This suggests that prolonging taper duration offers no advantage, and patients should be counseled that most will require ongoing maintenance therapy rather than successful discontinuation.
Special Considerations
Chronic pain patients: Cross-titration protocols show only 48% success rates, with highly variable responses requiring individualized approaches 3, 4. Average final doses were 7.9 mg/day, with induction taking approximately 29 days—substantially longer than the standard OUD induction.
Re-induction after full agonist use: When restarting buprenorphine after treatment with full opioid agonists (e.g., for acute pain management), patients must be in mild withdrawal before buprenorphine administration to avoid precipitated withdrawal 2.
Common Pitfalls
- Starting too early: Administering buprenorphine before adequate withdrawal onset precipitates severe withdrawal
- Underdosing: Using <8 mg daily maintenance doses shows inferior treatment retention
- Assuming taper success: Only 12-18% remain opioid-free 3 months after any taper schedule; most patients require indefinite maintenance
The evidence strongly supports rapid titration to 16 mg daily within 2-3 days for optimal treatment retention and reduction in illicit opioid use 1.